Matched-pair analysis to compare the outcomes of a second salvage auto-SCT to systemic chemotherapy alone in patients with multiple myeloma who relapsed after front-line auto-SCT

被引：0

作者：

H-Y Yhim

K Kim

J S Kim

H J Kang

J-A Kim

C-K Min

S H Bae

E Park

D-H Yang

C Suh

M K Kim

Y-C Mun

H S Eom

H J Shin

H-J Yoon

J H Kwon

J H Lee

Y S Kim

S-S Yoon

J-Y Kwak

机构：

[1] Chonbuk National University Medical School,Department of Internal Medicine

[2] Research Institute of Clinical Medicine of Chonbuk National University-Biomedical Research Institute of Chonbuk National University Hospital,Department of Medicine, Division of Hematology and Oncology

[3] Samsung Medical Center,Department of Internal Medicine, Division of Hematology

[4] Sungkyunkwan University School of Medicine,Department of Internal Medicine

[5] Yonsei University College of Medicine,Department of Hematology

[6] Korea Cancer Center Hospital,Department of Hematology

[7] St Vincent Hospital,Department of Internal Medicine

[8] Catholic University of Korea College of Medicine,Department of Hematology–Oncology

[9] Kangnam St Mary’s Hospital,Department of Oncology

[10] Catholic University of Korea College of Medicine,Department of Internal Medicine

[11] Daegu Catholic University Medical Center,Department of Internal Medicine

[12] Department of Internal Medicine Chung-Ang University College of Medicine,Department of Internal Medicine

[13] Chonnam National University Hwasun Hospital,Department of Hematology–Oncology

[14] Asan Medical Center,Department of Internal Medicine

[15] University of Ulsan College of Medicine,Department of Internal Medicine

[16] Yeungnam University College of Medicine,Department of Internal Medicine

[17] Ewha Woman’s University School of Medicine,Department of Internal Medicine

[18] Center for Specific Organs Cancer,undefined

[19] National Cancer Center of Korea,undefined

[20] Pusan National University School of Medicine,undefined

[21] School of Medicine,undefined

[22] Kyung Hee University,undefined

[23] Kangdong Sacred Heart Hospital,undefined

[24] Hallym University Medical Center,undefined

[25] Gachon University Gil Hospital,undefined

[26] Kosin University Gospel Hospital,undefined

[27] Seoul National University College of Medicine,undefined

来源：

Bone Marrow Transplantation | 2013年 / 48卷

关键词：

auto-SCT; multiple myeloma; salvage therapy;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

The aims of this study were to investigate the outcomes of second salvage auto-SCT and to identify the impacts of a second auto-SCT compared with systemic chemotherapy alone on disease outcome. Data from 48 patients who underwent second auto-SCT were matched to 144 patients (1:3) who received systemic chemotherapy alone from the Korean Myeloma Registry. Groups were matched for nine potential prognostic factors and compared for treatment outcomes. The median age of matching-pairs at relapse was 55.5 years. A total of 156 patients (81%) received vincristine, doxorubicin and dexamethasone induction therapy before the first auto-SCT. Thirty-five patients (73%) in the second auto-SCT group received novel agent-based therapies before the second auto-SCT, and similar proportion in both groups received novel therapies after relapse of front-line auto-SCT. With a median follow-up of 55.3 months, patients who underwent a second auto-SCT had significantly better median OS (55.5 vs 25.4 months, P=0.035). In multivariate analysis for OS, <18 months time to progression after first auto-SCT, International Staging System III and salvage chemotherapy alone were independent predictors for worse OS. The outcomes of second auto-SCT appear to be superior to those of systemic chemotherapy alone. A randomized trial comparing both treatment strategies is required.

引用

页码：425 / 432

页数：7

共 31 条

[21] Comparison of outcomes after auto-SCT for patients with relapsed diffuse large B-cell lymphoma according to previous therapy with rituximab
S D Smith
B J Bolwell
L A Rybicki
T Kang
R Dean
A Advani
S Thakkar
R Sobecks
M Kalaycio
B Pohlman
J W Sweetenham
Bone Marrow Transplantation, 2011, 46 : 262 - 266
[22] Outcomes for HIV-positive patients with primary central nervous system lymphoma after high-dose chemotherapy and auto-SCT
O'Neill, A.
Mikesch, K.
Fritsch, K.
Kasenda, B.
Banerjee, L.
Burns, F.
Zakout, G.
Johnston, R.
Illerhaus, G.
Cwynarski, K.
BONE MARROW TRANSPLANTATION, 2015, 50 (07) : 999 - 1000
[23] Outcomes for HIV-positive patients with primary central nervous system lymphoma after high-dose chemotherapy and auto-SCT
A O'Neill
K Mikesch
K Fritsch
B Kasenda
L Banerjee
F Burns
G Zakout
R Johnston
G Illerhaus
K Cwynarski
Bone Marrow Transplantation, 2015, 50 : 999 - 1000
[24] Retraction Note: First-line thalidomide–dexamethasone therapy in preparation for auto-SCT in young patients (<61 years) with symptomatic multiple myeloma
A Abdelkefi
L Torjman
N Ben Romdhane
S Ladeb
H El Omri
T Ben Othman
M Elloumi
H Bellaj
A Lakhal
R Jeddi
L Aissaouï
A Saad
M Hsaïri
K Boukef
K Dellagi
A Ben Abdeladhim
Bone Marrow Transplantation, 2009, 43 : 893 - 893
[25] COMPARISON BETWEEN 8-COLOR MULTIPARAMETER FLOW CYTOMETRY AND NEXT-GENERATION SEQUENCING TO DETECT MINIMAL RESIDUAL DISEASE IN MULTIPLE MYELOMA PATIENTS WHO UNDERWENT AUTO-SCT
Takamatsu, H.
Wee, R.
Takezako, N.
Zheng, J.
Carlton, V.
Moorhead, M.
Yoshida, T.
Faham, M.
Nakao, S.
HAEMATOLOGICA, 2016, 101 : 535 - 535
[26] Radioimmunotherapy with 90Y-ibritumomab tiuxetan is a safe and efficient treatment for patients with B-cell lymphoma relapsed after auto-SCT: an analysis of the international RIT-Network
Hohloch, K.
Zinzani, P. L.
Linkesch, W.
Jurczak, W.
Deptala, A.
Lorsbach, M.
Windemuth-Kiesselbach, C.
Wulf, G. G.
Truemper, L. H.
BONE MARROW TRANSPLANTATION, 2011, 46 (06) : 901 - 903
[27] First-line thalidomide-dexamethasone therapy in preparation for auto-SCT in young patients (<61 years) with symptomatic multiple myeloma (Retraction of vol 36, pg 193, 2005)
Abdelkefi, A.
Torjman, L.
Romdhane, N. Ben
Ladeb, S.
El Omri, H.
Othman, T. Ben
Elloumi, M.
Bellaj, H.
Lakhal, A.
Jeddi, R.
Aissaoui, L.
Saad, A.
Hsairi, M.
Boukef, K.
Dellagi, K.
Abdeladhim, A. Ben
BONE MARROW TRANSPLANTATION, 2009, 43 (11) : 893 - 893
[28] Radioimmunotherapy with 90Y-ibritumomab tiuxetan is a safe and efficient treatment for patients with B-cell lymphoma relapsed after auto-SCT: an analysis of the international RIT-Network
K Hohloch
P L Zinzani
W Linkesch
W Jurczak
A Deptala
M Lorsbach
C Windemuth-Kiesselbach
G G Wulf
L H Truemper
Bone Marrow Transplantation, 2011, 46 : 901 - 903
[29] BORTEZOMIB-BASED THERAPY INCREASES THE INCIDENCE OF POST-TRANSPLANT VIRAL INFECTIONS IN MULTIPLE MYELOMA PATIENTS UNDERGOING AUTO-SCT: A RETROSPECTIVE ANALYSIS FROM THE ROME TRANSPLANT NETWORK
Marchesi, F.
Mengarelli, A.
Angelini, S.
Giannotti, F.
Porrini, R.
Picardi, A.
Chierichini, A.
Cerchiara, E.
Dentamaro, T.
Cudillo, L.
Anaclerico, B.
Tendas, A.
Montefusco, E.
Romano, A.
Tirindelli, M.
De Fabritiis, P.
Annino, L.
Petti, M.
Monarca, B.
Avvisati, G.
Arcese, W.
HAEMATOLOGICA, 2012, 97 : 354 - 354
[30] High-dose chemotherapy and autologous peripheral blood stem cell rescue (Auto-SCT) in multiple myeloma (MM) patients: Busulfan plus melphalan-140 (BuMel) versus (vs) melphalan-200 (Mel-200) as conditioning regimens.
Carrion Galindo, R., Sr.
Serrano, D.
Perez-Corral, A.
Balsalobre, P.
Buno, I.
Anguita, R.
Gomez-Pineda, A.
Mayayo, M.
Diez-Martin, J.
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 449S - 449S

← 1 2 3 4 →